Intramedullary Nailing for Femoral Shaft Fractures
Comparative Effectiveness Randomized Controlled Trial of Micromotion vs Non-micromotion Intramedullary Nailing for Femoral Shaft Fractures
A randomized controlled trial that is trying to find the best treatment for a severe upper leg (i.e., thigh, also known as femoral shaft) fracture. One type of treatment, which is called micromotion intramedullary (within the hollow center of the bone) nailing, is a type of nail used for thigh fracture treatments that helps to heal the bone by allowing a small amount of controlled movement. Another type, called non-micromotion intramedullary nailing, is also used to treat thigh fractures but does not include this controlled-movement feature. Both treatments are approved by the FDA but have not been directly compared to each other. Participation includes being assigned to receive either a micromotion intramedullary nail or a non-micromotion intramedullary nail. Those that participate will be randomly assigned (like a flip of a coin) to one of those treatment methods and return for standard follow-up visits. In addition to those regular clinical follow-ups, participants will complete some brief surveys/questionnaires while they are in the hospital. Research staff will also look at past medical history.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Health Methodist Hospital
-
Principal Investigator:
- Roman Natoli, MD, PhD
-
Contact:
- Cora F Mizimakoski, Bachelor of Science
- Phone Number: 317-963-5034
- Email: cmizimak@iu.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18-84 years old inclusive with a femoral shaft fracture deemed appropriate for treatment with an IMN by the treating surgeon
Exclusion Criteria:
- Not within age range
- Planned treatment with dominant implants other than IMN
- Non-ambulatory at baseline
- Fracture needs a planned-staged secondary procedure for bone defects (e.g., Masquelet)
- Any previous surgery on the index site
- Fracture fixation >28 days from injury
- Fractures that the treating surgeon indicates require any additional fixation that spans the fracture. These patients will be late ineligible
- Patients with a history of infection or a current active infection at the surgical site
- Patients undergoing revision surgery following primary fixation
- Patients undergoing femoral nailing for a pathological fracture
- Patients undergoing bone transport over an intramedullary nail
- Non-English or Non-Spanish speaking
- Prisoners or impending incarceration
- Patients unwilling or unable to participate in study protocol or follow up in the IU system for 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard Intramedullary Nailing
|
A rod inserted into the hollow center of a long bone to hold a broken bone in place while it heals. |
|
Experimental: OrthoXel Micromotion Intramedullary Nail
|
An intramedullary nail that allows for controlled axial micromotion. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Superiority of micromotion nailing over non-micromotion IMN according to a composite outcome using a win ratio reflective of improved femoral shaft fracture healing
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Iindividual levels of the win-ratio pyramid between the micromotion nailing and non-micromotion nailing groups.
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
|
|
Superiority of micromotion nailing in a subgroup of patients at high baseline risk for nonunion.
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
|
|
Number of patients with Adverse Events and Complications between the Micromotion nail and standard of care intramedullary nails.
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
|
|
Change in daily step count from pre-injury baseline between the micromotion nailing and non-micromotion nailing groups.
Time Frame: From enrollment to end of treatment at about a year.
|
Daily step count, measured in steps per day, will be obtained from the Apple Health app on the participant's iPhone. Participants will download the OrthoSteps app once to transfer their Apple Health data to the study team. Step counts will be assessed at the pre-injury baseline and at each post-injury follow-up. |
From enrollment to end of treatment at about a year.
|
|
Gait balance between the two groups as calculated by the GaitMap.
Time Frame: From enrollment to end of treatment at about a year
|
From enrollment to end of treatment at about a year
|
|
|
Walking speed using a GaitMap
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
|
|
Modified Radiographic union scores for femoral shaft fractures
Time Frame: From enrollment to end of treatment at about a year.
|
From enrollment to end of treatment at about a year.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Roman Natoli, MD, PhD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 29753
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.